You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動丨步長製藥漲4.37% 國家高層重視中醫藥發展 三季度業績再次實現增長
格隆匯 10-28 11:31
格隆匯10月28日丨步長製藥(603858.SH)漲4.37%,報20.32元,總市值232億元。步長製藥上週五發布2019年第三季度業績報告,公告顯示,步長製藥前三季度營業收入102.42億元,同比增加10.29%,歸屬上市公司股東的淨利潤13.49億元,同比增加10.97%。國家主席習近平近日對中醫藥工作作出重要指示,要遵循中醫藥發展規律,傳承精華,守正創新,加快推進中醫藥現代化、產業化,堅持中西醫並重,推動中醫藥和西醫藥相互補充、協調發展,推動中醫藥事業和產業高質量發展,推動中醫藥走向世界。步長製藥是國內領先的中成藥企業。據步長製藥半年報顯示,步長製藥已擁有294件國家專利。其中,主導產品腦心通膠囊、穩心顆粒、丹紅注射液、谷紅注射液均為專利保護品種。專利中藥優勢給予了步長製藥持續發展的信心,在4+7帶量採購政策的影響下,仿製藥或將受到打擊,而在這一波產業創新升級浪潮中,行業龍頭的地位將更加穩固。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account